CHLORAMPHENICOL PALMITATE

US Previously Marketed

First approved in 1950

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H42Cl2N2O6
Molecular Weight	561.538
Optical Activity	( - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O

InChI

InChIKey=PXKHGMGELZGJQE-ILBGXUMGSA-N

InChI=1S/C27H42Cl2N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-24(32)37-20-23(30-27(34)26(28)29)25(33)21-16-18-22(19-17-21)31(35)36/h16-19,23,25-26,33H,2-15,20H2,1H3,(H,30,34)/t23-,25-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C27H42Cl2N2O6
Molecular Weight	561.538
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.acutetox.eu/pdf_human_short/74-Chloramphenicol%20revised.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20930076

Chloramphenicol is a broad-spectrum antibiotic that was first isolated from Streptomyces venezuelae in 1947. The drug was subsequently chemically synthesized. It has both a bacteriostatic and bactericidal effect; in the usual therapeutic concentrations it is bacteriostatic. Chloramphenicol is used for the treatment of serious gram-negative, gram-positive, and anaerobic infections. It is especially useful in the treatment of meningitis, typhoid fever, and cystic fibrosis. It should be reserved for infections for which other drugs are ineffective or contraindicated. Chloramphenicol, a small inhibitor of bacterial protein synthesis, is active against a variety of bacteria and readily enters the CSF. It has been used extensively in the last decades for the treatment of bacterial meningitis. In industrialized countries, chloramphenicol is restricted mostly to topical uses because of the risk of induction of aplastic anemia. However, it remains a valuable reserve antibiotic for patients with allergy to β-lactam antibiotics or with CNS infections caused by multiresistant pathogens.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
intestinal esterase 7 Target ID: intestinal esterase Sources: https://www.iasj.net/iasj?func=article&aId=41875	Substrate 661
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4599122 \| https://www.ncbi.nlm.nih.gov/pubmed/324517	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eye infections 13 Sources: https://www.medicines.org.uk/emc/PIL.29903.latest.pdf	Curative		Approved 8583	CHLOROPTIC Approved Use Indications and Usage In accord with the concepts in the Warning Box and this section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above. 1. Acute infections caused by Salmonella typhi* It is not recommended for the routine treatment of the typhoid carrier state. 2. Serious infections caused by susceptible strains in accordance with the concepts expressed above: a) Salmonella species b) H. influenzae, specially meningeal infections c) Rickettsia d) Lymphogranuloma-psittacosis group e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents. 3. Cystic fibrosis regimens *In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse. Launch Date 1968

C_max

Value	Dose	Co-administered	Analyte	Population
16.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
59.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/	25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/	25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL SUCCINATE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	unhealthy, 0.5 - 12 years Health Status: unhealthy Age Group: 0.5 - 12 years Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	Other AEs: Swollen eyelid... Other AEs: Swollen eyelid (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/
0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 11 years Health Status: unhealthy Age Group: 11 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	unhealthy, 15 years Health Status: unhealthy Age Group: 15 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	Disc. AE: Hyperlactatemia... AEs leading to discontinuation/dose reduction: Hyperlactatemia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/
3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 23 years Health Status: unhealthy Age Group: 23 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 27 years Health Status: unhealthy Age Group: 27 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 54 years Health Status: unhealthy Age Group: 54 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 61 years Health Status: unhealthy Age Group: 61 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 68 years Health Status: unhealthy Age Group: 68 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 71 years Health Status: unhealthy Age Group: 71 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
3 % 1 times / day multiple, topical Recommended Dose: 3 %, 1 times / day Route: topical Route: multiple Dose: 3 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/	Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/

AEs

AE	Significance	Dose	Population
Swollen eyelid	1 patient	0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	unhealthy, 0.5 - 12 years Health Status: unhealthy Age Group: 0.5 - 12 years Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/
Aplastic anemia	grade 4, 1 patient Disc. AE	0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 11 years Health Status: unhealthy Age Group: 11 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Hyperlactatemia	1 patient Disc. AE	70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	unhealthy, 15 years Health Status: unhealthy Age Group: 15 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/
Aplastic anemia	grade 5, 1 patient Disc. AE	3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 23 years Health Status: unhealthy Age Group: 23 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 27 years Health Status: unhealthy Age Group: 27 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 54 years Health Status: unhealthy Age Group: 54 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 61 years Health Status: unhealthy Age Group: 61 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 68 years Health Status: unhealthy Age Group: 68 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 71 years Health Status: unhealthy Age Group: 71 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252		inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A 70 CYP2A6 879 CYP2B6 926 CYP2C19 2057 CYP2E1 1060 CYP2C8/9 42

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/	no [IC50 375.9 uM]
CYP1A 122	inhibitor 4027 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2A6 911	inhibitor 4027 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2C8/9 42	inhibitor 4027 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/, https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	yes [IC50 32 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/	yes [IC50 48.1 uM]

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01359	http://www.3bsc.com/index/pro_info.php?id=21571
3B Scientific (Wuhan) Corp	3B1-01423	http://www.3bsc.com/index/pro_info.php?id=21635
3B Scientific (Wuhan) Corp	3B2-0144	http://www.3bsc.com/index/pro_info.php?id=19500
abcr GmbH	AB125782	http://www.abcr.com/shop/en/AB125782
AbMole Bioscience	M4901	http://www.abmole.com/products/chloramphenicol.html
Achemo Scientific Limited	AC-11414	http://www.achemo.com/product_view.asp?ID=1304
Achemtek	0104-014718	http://www.achemtek.com/56-75-7
Acros Organics	AC227920250	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics-1/AC227920250
Acros Organics	AC227921000	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics/AC227921000
Acros Organics	AC227925000	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics-2/AC227925000
Adooq BioScience	A10200	https://www.adooq.com/chloramphenicol.html
AHH Chemical co.,ltd	API-1130	http://www.ahhchemical.com/product/API-1130.html
AK Scientific, Inc. (AKSCI)	M163	http://www.aksci.com/item_detail.php?cat=M163
Alfa Aesar	B20841	https://www.alfa.com/en/catalog/B20841/
Alfa Chemistry	AP56757-A	https://reagents.alfa-chemistry.com/product/chloramphenicol-cas-56-75-7-13261.html
Alfa Chemistry	AP56757-B	https://reagents.alfa-chemistry.com/product/chloramphenicol-cas-56-75-7-13262.html
Angene	AGN-PC-0SMDXX	http://www.angenechemical.com/productshow/AGN-PC-0SMDXX.html
ApexBio Technology	A2512	http://www.apexbt.com/chloramphenicol.html
Aronis	ARONIS23913	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1185
Aurora Fine Chemicals LLC	K04.629.929	http://online.aurorafinechemicals.com/info?ID=K04.629.929
Aurum Pharmatech LLC	W-2830	http://www.Aurumpharmatech.com/Product/ProductDetails/W_2830
Avantor Inc	101094-576	https://us.vwr.com/store/product/7889372/chloramphenicol
Avantor Inc	200002-782	https://us.vwr.com/store/product/7517958/chloramphenicol
BioChemPartner	BCP12150	http://www.biochempartner.com/56-75-7-BCP12150
BioSynth	C-3307	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/C-3307.html
Calbiochem	220551	http://www.emdbiosciences.com/product/220551
Capot Chemical	20321	http://www.capotchem.com/en/20321.htm
Capot Chemical	PubChem20321	http://www.capotchem.com/en/20321.htm
Chem Scene	CS-2207	http://www.chemscene.com/56-75-7.html
Chemenu	CM110456	http://www.chemenu.com/products/CM110456
ChemMol	80101190	http://www.chemmol.com/chemmol/80101190.html
ChemMol	99159330	http://www.chemmol.com/chemmol/99159330.html
Chemspace	CSSB00000037240	https://chem-space.com/CSSB00000037240
Chiralblock Biosciences	CB11330	http://www.chiralblock.com/products/56-75-7.html
Clearsynth	CS-O-11618	https://www.clearsynth.com/en/CSO11618.html
DC Chemicals	DCAPI1255	http://www.dcchemicals.com//product_show-Chloramphenicol_Chloromycetin_.html
EMD Millipore	220551	http://www.emdbiosciences.com/product/220551
eNovation Chemicals	D397703	http://www.enovationchem.com/productDetails.asp?productID=D397703
Glentham Life Sciences	GA0258	http://www.glentham.com/products/product/GA0258/
iChemical	EBD2198129	http://www.ichemical.com/products/56-75-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00159574	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00159574
LGC Standards	DRE-C11120000	https://www.lgcstandards.com/US/en/p/DRE-C11120000
LGC Standards	DRE-L11120000AL	https://www.lgcstandards.com/US/en/p/DRE-L11120000AL
LGC Standards	DRE-XA11120000EA	https://www.lgcstandards.com/US/en/p/DRE-XA11120000EA
LGC Standards	LGCFOR0516.00	https://www.lgcstandards.com/US/en/p/LGCFOR0516.00
LGC Standards	MM0516.00	https://www.lgcstandards.com/US/en/p/MM0516.00
Matrix Scientific	58319	https://www.matrixscientific.com/058319.html
mcule	MCULE-7778960570	https://mcule.com/MCULE-7778960570/
MedChem Express	HY-B0239	https://www.medchemexpress.com/Chloramphenicol.html
MuseChem	A001107	https://www.musechem.com/product/A001107.html
MuseChem	M114534	https://www.musechem.com/product/M114534.html
Oakwood	492377	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=193461&ExtHyperLink=1
Sigma-Aldrich	1107004_USP	https://www.sigmaaldrich.com/catalog/product/usp/1107004?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	23276_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/23276?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	31667_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/31667?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	75565_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/75565?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP854_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp854?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S772648	https://www.smolecule.com/products/s772648
Synblock Inc	AB02994	http://www.synblock.com/product/56-75-7.html
TCI (Tokyo Chemical Industry)	C2255	http://www.tcichemicals.com/eshop/en/us/commodity/C2255/index.html
THE BioTek	bt-295295	https://www.thebiotek.com/product/others/bt-295295
THE BioTek	bt-458998	https://www.thebiotek.com/product/others/bt-458998
VladaChem	VL141192	https://www.vladachem.com/product.php?products=56-75-7

PubMed

Title	Date	PubMed
UV-induced increase in RNA polymerase activity in Xanthomonas oryzae pathovar oryzae.	2001-08	11391475
A novel heat shock protein plays an important role in thermal stress management in cyanobacteria.	2001-07-06	11342543
Antibacterial activity of 4,5-dihydroxy-2-cyclopentan-1-one (DHCP) and cloning of a gene conferring DHCP resistance in Escherichia coli.	2001-07	11361079
Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom.	2001-06-01	11384525
Secretion of the virulence-associated Campylobacter invasion antigens from Campylobacter jejuni requires a stimulatory signal.	2001-06-01	11343209
Cloning and functional analysis of a phosphopantetheinyl transferase superfamily gene associated with jadomycin biosynthesis in Streptomyces venezuelae ISP5230.	2001-06	11390684
Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain.	2001-06	11389119
External quality assessment of antimicrobial susceptibility testing in Europe.	2001-06	11389112
Screening of antibiotic resistant inhibitors from local plant materials against two different strains of Pseudomonas aeruginosa.	2001-06	11378279
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India.	2001-05-24	11370501
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.	2001-05-15	11320453
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.	2001-05-15	11320449
Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas.	2001-05-08	11340403
Clostridium sordelii corneal ulcer.	2001-05-08	11339473
Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997-2000.	2001-05-01	11381628
Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.	2001-05-01	11303275
Increased mitochondrial-encoded gene transcription in immortal DF-1 cells.	2001-05-01	11302700
Induction of complement sensitivity in Escherichia coli by citric acid and low pH.	2001-05	11348438
Natural antibiotic susceptibility of Klebsiella pneumoniae, K. oxytoca, K. planticola, K. ornithinolytica and K. terrigena strains.	2001-05	11339246
In vitro susceptibility of Vibrio spp. isolated from the environment.	2001-05	11337229
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.	2001-05	11337227
In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico.	2001-05	11337225
Carriage of antibiotic-resistant bacteria by healthy children.	2001-05	11328771
Comparative study of the influence of melatonin and vitamin E on the surface characteristics of Escherichia coli.	2001-05	11328494
Plasmid transfer and susceptibility to antibiotics in the halophilic phototrophs Rhodovibrio salinarum and Rhodothalassium salexigens.	2001-04-01	11287156
Disposition kinetics of florfenicol in goats by using two analytical methods.	2001-04	11379386
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.	2001-04	11330362
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia.	2001-04	11330361
Strain differences in haematological response to chloramphenicol succinate in mice: implications for toxicological research.	2001-04	11295484
Randomised controlled trial of ketorolac in the management of corneal abrasions.	2001-04	11284758
[Susceptibility of non-typhi Salmonella spp. at the Galdakao Hospital (1992-1998)].	2001-03	11376350
Analysis of a conserved hydrophobic pocket important for the thermostability of Bacillus pumilus chloramphenicol acetyltransferase (CAT-86).	2001-03	11342712
Occurrence of the vanA and vanC2/C3 genes in Enterococcus species isolated from poultry sources in Malaysia.	2001-03	11337180
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.	2001-03	11315521
Antimicrobial susceptibility of Listeria monocytogenes isolated from meningoencephalitis in sheep.	2001-03	11282267
Antimicrobial resistance of Enterococci in Lebanon.	2001-03	11282266
Liposome-mediated DNA uptake and transient expression in Thermotoga.	2001-02	11302503
Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia.	2001-02	11293678
Interaction of human aldehyde dehydrogenase with aromatic substrates and ligands.	2001-01-30	11306037
A limited loss of DNA compaction accompanying the release of cytoplasm from cells of Escherichia coli.	2001-01	11356066
Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia.	2001-01	11284938
Survey of yeast mastitis in dairy herds of small-type farms in the Lublin region, Poland.	2001	11392567
Carbon and nitrogen removal from a wastewater of an industrial dairy laboratory with a coupled anaerobic filter-sequencing batch reactor system.	2001	11381913
Numerical methods for handling uncertainty in microarray data: an example analyzing perturbed mitochondrial function in yeast.	2001	11381609
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA.	2001	11327109
Amplification of the Escherichia coli lacZ gene in Bacillus subtilis and its expression on a by-product growth medium.	2001	11314242
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.	2001	11310804
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.	2001	11310803
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.	2001	11310802
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods.	2001	11310799

Patents

Sample Use Guides

In Vivo Use Guide

Chloramphenicol 0.5% Eye Drops

Route of Administration: Topical

In Vitro Use Guide

The highest activity of chloramphenicol was documented for isolates of Stenotrophomonas maltophilia (76,5 % susceptible, MIC50 = 4 mg/L, MIC90 = 16 mg/L) and of Staphylococcus aureus (76,2 % susceptible, MIC50 = 8 mg/L, MIC90 = 16 mg/L).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:36:52 GMT 2025` Edited by `admin` on `Mon Mar 31 17:36:52 GMT 2025`
Record UNII	43VU4207NW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORAMPHENICOL PALMITATE

Common Name

English

CHLORAMPHENICOL PALMITATE NONPOLYMORPH A

Preferred Name

English

CHLORAMPHENICOL PALMITATE POLYMORPH A

Common Name

English

CHLORAMPHENICOL PALMITATE [VANDF]

Common Name

English

CHLORAMPHENICOL PALMITATE [MI]

Common Name

English

CHLORAMPHENICOL PALMITATE [JAN]

Common Name

English

CHLORAMPHENICOL PALMITATE POLYMORPH A [USP-RS]

Common Name

English

CHLORAMPHENICOL PALMITATE [USP IMPURITY]

Common Name

English

DETREOPAL

Common Name

English

CHLORAMPHENICOL PALMITATE [EP MONOGRAPH]

Common Name

English

CHLORAMPHENICOL PALMITATE [GREEN BOOK]

Common Name

English

CHLORAMPHENICOL PALMITATE [USP MONOGRAPH]

Common Name

English

CLOROLIFARINA

Common Name

English

CHLORAMPHENICOL PALMITATE [ORANGE BOOK]

Common Name

English

HEXADECANOIC ACID, 2-((2,2-DICHLOROACETYL)AMINO)-3-HYDROXY-3-(4-NITROPHENYL)PROPYL ESTER, (R-(R*,R*))-

Common Name

English

CHLORAMPHENICOL PALMITATE [MART.]

Common Name

English

NSC-756675

Code

English

CHLORAMBON

Common Name

English

CHLORAMPHENICOL PALMITATE [WHO-IP]

Common Name

English

CHLORAMPHENICOLI PALMITAS [WHO-IP LATIN]

Common Name

English

CHLORAMPHENICOL PALMITATE NONPOLYMORPH A [USP-RS]

Common Name

English

D-THREO-(-)-2,2-DICHLORO-N-(.BETA.-HYDROXY-.ALPHA.-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE .ALPHA.-PALMITATE

Common Name

English

Chloramphenicol palmitate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C258